Chiesi Farmaceutici S.p.A. (commonly known as Chiesi Group) is a major Italian pharmaceutical company headquartered in Parma, Italy. Founded in 1935, Chiesi has grown from a local family-owned business into a global pharmaceutical powerhouse with operations in over 30 countries and a focus on respiratory diseases, rare diseases, and specialty therapeutics. The company is particularly notable for its commitment to rare disease therapies, including the acquisition of Apopharma and its development of iron chelation therapies for Parkinson's disease.
Chiesi's mission centers on improving patient lives through innovative medicines, with particular emphasis on respiratory conditions, neonatology, and rare diseases. The company's acquisition of Apopharma in 2014 expanded its portfolio into neurodegenerative disease development, specifically deferiprone for Parkinson's disease through the landmark FAIRPARK clinical trials.
| Attribute | Details |
|---|---|
| Founded | 1935 |
| Headquarters | Parma, Italy |
| CEO | Giuseppe Accogli |
| Revenue | €2.4 Billion (2024) |
| Employees | ~6,500 |
| Global Presence | 30+ countries |
| Focus Areas | Respiratory, Rare Diseases, Neonatology |
| Status | Private (Family-owned) |
Chiesi Farmaceutici was founded in 1935 by Giacomo Chiesi in Parma, Italy. The company began as a small pharmaceutical laboratory focused on producing essential medicines for the local market. The early decades focused on establishing manufacturing capabilities and building a reputation for quality pharmaceutical products in Italy.
Key early milestones:
The company underwent significant expansion beginning in the 1980s:
A pivotal moment in Chiesi's history was the 2014 acquisition of Apopharma Inc., an Italian pharmaceutical company specializing in iron chelation therapies. The acquisition provided Chiesi with:
The FAIRPARK clinical trials for deferiprone in Parkinson's disease positioned Chiesi as a leader in disease-modifying therapies for neurodegenerative disorders.
Chiesi is a global leader in respiratory medicine, with a comprehensive portfolio of treatments for:
Key products include:
The Rare Diseases division, which includes Apopharma, focuses on:
| Condition | Product | Status |
|---|---|---|
| Iron overload | Deferiprone | Approved |
| Thalassemia | Deferiprone | Approved |
| Parkinson's disease | Deferiprone | Phase II |
| Lysosomal storage disorders | Various | Development |
Chiesi's neonatology division provides specialized products for:
Chiesi maintains significant R&D capabilities:
Current R&D priorities include:
Chiesi has conducted extensive clinical trials:
| Region | Status | Key Markets |
|---|---|---|
| Europe | Primary | Italy, Germany, France, UK, Spain |
| North America | Growing | USA, Canada |
| Asia-Pacific | Expansion | Japan, China, Australia |
| Latin America | Established | Brazil, Mexico, Argentina |
Chiesi operates cGMP manufacturing facilities:
| Year | Revenue (€) | Key Drivers |
|---|---|---|
| 2020 | €1.9B | Respiratory portfolio |
| 2021 | €2.1B | US expansion |
| 2022 | €2.3B | Rare disease growth |
| 2023 | €2.4B | New product launches |
| 2024 | €2.4B | Steady performance |
Chiesi consistently invests in R&D:
Chiesi is committed to sustainable business practices:
| Company | Area | Notes |
|---|---|---|
| GSK | Respiratory | Global leader |
| AstraZeneca | Respiratory | Strong pipeline |
| Novartis | Rare diseases | Competitive portfolio |
| Teva | Generic respiratory | Cost pressure |
While Chiesi is primarily known for respiratory and rare diseases, their acquisition of Apopharma demonstrates interest in neurodegenerative diseases:
Chiesi (through Apopharma) supported the FAIRPARK clinical trials:
The Parkinson's disease program represents: